

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Holick *et al.*

Appl. No.: 10/518,618

§ 371 Date: December 22, 2004

For: **Conjugates Comprising an NSAID
and a Sugar and Uses Thereof**

Confirmation No.: 8983

Art Unit: 1609

Examiner: Westerberg, Nissa M.

Atty. Docket: 1539.0430001/RWE

Reply to Requirement For Election of Species

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

Mail Stop Amendment

Sir:


In reply to the Office Action dated July 31, 2007, Applicants hereby provisionally elect the second naproxan-glucosamine conjugate depicted in paragraph [0017] of the application. Claims 1, 2 and 8-11 read on such species. This election is made without prejudice to or disclaimer of the other claims or inventions disclosed.

This election is made **with traverse**.

It is believed that extensions of time are not required, beyond those that may otherwise be provided for in accompanying documents. However, in the event that additional extensions of time are necessary to prevent abandonment of this application, then such extensions of time are hereby petitioned under 37 C.F.R. § 1.136(a), and any fees required therefor are hereby authorized to be charged to our Deposit Account No. 19-0036.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.



Robert W. Esmond
Attorney for Applicants
Registration No. 32,893

Date: November 16, 2007

1100 New York Avenue, N.W.
Washington, D.C. 20005-3934
(202) 371-2600